| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| host | mouse |
| isotype | IgG1 |
| clonality | monoclonal |
| concentration | 1 mg/mL |
| applications | ICC/IF, WB |
| reactivity | cdc34 |
| available sizes | 100 µg |
mouse anti-cdc34 monoclonal antibody (14B5) 7470
$503.00
Antibody summary
- Mouse monoclonal to cdc34
- Suitable for: WB,ICC/IF,IHC-P,IP
- Isotype: IgG1
- 100 µg
mouse anti-cdc34 monoclonal antibody (14B5) 7470
| antibody |
|---|
| Tested applications WB,IHC,IHC,ICC/IF |
| Recommended dilutions Immunoblotting and Immuno-precipitation: use at 1-5 ug/mL. Positive controls: 293 cells and recombinant fusion protein. |
| Immunogen N-terminus 6x-His tagged fusion protein encoding full-length human Cdc34 expressed in E. coli. |
| Size and concentration 100µg and lot specific |
| Form liquid |
| Storage Instructions This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze- thaw cycles. |
| Storage buffer 10 mM PBS, pH 7.4. |
| Purity immunogen affinity purification |
| Clonality monoclonal |
| Isotype IgG1 |
| Compatible secondaries goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody 5486 goat anti-mouse IgG, H&L chain specific, biotin conjugated, Conjugate polyclonal antibody 2685 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody 7854 goat anti-mouse IgG, H&L chain specific, peroxidase conjugated polyclonal antibody, crossabsorbed 1706 goat anti-mouse IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1716 goat anti-mouse IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1721 |
| Isotype control Mouse monocolonal IgG1 - Isotype Control |
| target relevance |
|---|
| Protein names Ubiquitin-conjugating enzyme E2 R1 (EC 2.3.2.23) ((E3-independent) E2 ubiquitin-conjugating enzyme R1) (EC 2.3.2.24) (E2 ubiquitin-conjugating enzyme R1) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1) |
| Gene names CDC34,CDC34 UBCH3 UBE2R1 |
| Protein family Ubiquitin-conjugating enzyme family |
| Mass 26737Da |
| Function FUNCTION: E2 ubiquitin-conjugating enzyme that accepts ubiquitin from an E1 ubiquitin-activating protein, and catalyzes its covalent attachment to other proteins by an E3 ubiquitin-protein ligase complex (PubMed:10329681, PubMed:17588522, PubMed:20061386, PubMed:38326650). In vitro catalyzes 'Lys-48'-linked polyubiquitination (PubMed:22496338). Cooperates with the E2 UBCH5C and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation (PubMed:10329681, PubMed:10918611, PubMed:17698585). Performs ubiquitin chain elongation building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. UBE2D3 acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin. Cooperates with the SCF(SKP2) E3 ligase complex to regulate cell proliferation through ubiquitination and degradation of MYBL2 and KIP1 (PubMed:10871850, PubMed:15652359, PubMed:19112177). Involved in ubiquitin conjugation and degradation of CREM isoform ICERIIgamma and ATF15 resulting in abrogation of ICERIIgamma- and ATF5-mediated repression of cAMP-induced transcription during both meiotic and mitotic cell cycles. Involved in the regulation of the cell cycle G2/M phase through its targeting of the WEE1 kinase for ubiquitination and degradation (PubMed:19126550). Also involved in the degradation of beta-catenin (PubMed:12037680). Is target of human herpes virus 1 protein ICP0, leading to ICP0-dependent dynamic interaction with proteasomes (PubMed:11805320, PubMed:12060736). {ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:10871850, ECO:0000269|PubMed:10918611, ECO:0000269|PubMed:11805320, ECO:0000269|PubMed:12037680, ECO:0000269|PubMed:12060736, ECO:0000269|PubMed:15652359, ECO:0000269|PubMed:17588522, ECO:0000269|PubMed:17698585, ECO:0000269|PubMed:19112177, ECO:0000269|PubMed:19126550, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:22496338, ECO:0000269|PubMed:38326650}. |
| Catalytic activity CATALYTIC ACTIVITY: Reaction=S-ubiquitinyl-[E1 ubiquitin-activating enzyme]-L-cysteine + [E2 ubiquitin-conjugating enzyme]-L-cysteine = [E1 ubiquitin-activating enzyme]-L-cysteine + S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine.; EC=2.3.2.23; Evidence={ECO:0000255|PROSITE-ProRule:PRU00388, ECO:0000255|PROSITE-ProRule:PRU10133, ECO:0000269|PubMed:12037680, ECO:0000269|PubMed:17698585, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:20347421, ECO:0000269|PubMed:38326650}; CATALYTIC ACTIVITY: Reaction=S-ubiquitinyl-[E1 ubiquitin-activating enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E1 ubiquitin-activating enzyme]-L-cysteine + N(6)-monoubiquitinyl-[acceptor protein]-L-lysine.; EC=2.3.2.24; Evidence={ECO:0000269|PubMed:17588522}; |
| Pathway PATHWAY: Protein modification; protein ubiquitination. {ECO:0000269|PubMed:38326650}. |
| Subellular location SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=The phosphorylation of the C-terminal tail plays an important role in mediating nuclear localization. Colocalizes with beta-tubulin on mitotic spindles in anaphase. |
| Tissues TISSUE SPECIFICITY: Expressed in testes during spermatogenesis to regulate repression of cAMP-induced transcription. {ECO:0000269|PubMed:10373550}. |
| Structure SUBUNIT: Interacts with multiple Cul1-RING E3 ubiquitin-protein ligase complexes, also known as SCF (SKP1-CUL1-F-box protein) complexes (PubMed:10918611, PubMed:11675391, PubMed:18851830, PubMed:19112177, PubMed:19945379, PubMed:24316736). Identified in a SCF E3 ubiquitin ligase complex together with HINT1 and RBX1 (PubMed:19112177). When cullin is neddylated, the interaction between the E2 and the SCF complex is strengthened (PubMed:10918611, PubMed:11675391, PubMed:18851830, PubMed:19112177, PubMed:19945379, PubMed:24316736). Interacts with multiple Cul2-RING (CRL2) E3 ubiquitin-protein ligase complexes, also known as ECS (Elongin BC-CUL2/5-SOCS-box protein) complexes (PubMed:38326650). When phosphorylated, interacts with beta-TrCP (BTRC) (PubMed:12037680). Interacts with human herpes virus 1 protein ICP0 and associates with the proteasome for degradation (PubMed:11447293, PubMed:11805320, PubMed:12060736). Interacts with casein kinase subunit CSNK2B (PubMed:11546811). Interacts with CNTD1; this interaction regulates the cell-cycle progression (By similarity). {ECO:0000250|UniProtKB:Q8CFI2, ECO:0000269|PubMed:10918611, ECO:0000269|PubMed:11447293, ECO:0000269|PubMed:11546811, ECO:0000269|PubMed:11675391, ECO:0000269|PubMed:11805320, ECO:0000269|PubMed:12037680, ECO:0000269|PubMed:12060736, ECO:0000269|PubMed:18851830, ECO:0000269|PubMed:19112177, ECO:0000269|PubMed:19945379, ECO:0000269|PubMed:24316736}. |
| Post-translational modification PTM: Autoubiquitinated (PubMed:11805320, PubMed:12060736, PubMed:22496338). Autoubiquitination is promoted by the human herpes virus 1 protein ICP0 and leads to degradation by the Ubiquitin-proteasomal pathway (PubMed:11805320, PubMed:12060736). {ECO:0000269|PubMed:11805320, ECO:0000269|PubMed:12060736, ECO:0000269|PubMed:22496338}.; PTM: Phosphorylated by CK2. Phosphorylation of the C-terminal tail by CK2 controls the nuclear localization. {ECO:0000269|PubMed:11546811, ECO:0000269|PubMed:12037680, ECO:0000269|PubMed:17461777}. |
| Domain DOMAIN: The C-terminal acidic tail is required for nuclear localization and is involved in the binding to SCF E3 ligase complexes, and more specifically with the CUL1 subunit. {ECO:0000269|PubMed:10769200, ECO:0000269|PubMed:19945379}. |
| Target Relevance information above includes information from UniProt accession: P49427 |
| The UniProt Consortium |
Data
 |
| Sample (30 µg of whole cell lysate) A: A549 B: HCT116 10% SDS PAGE 7470 diluted at 1:1000 |
 |
| Immunohistochemical analysis of paraffin-embedded HBL435 xenograft, using CDC34(7470) antibody at 1:200 dilution. |
 |
| Immunofluorescence analysis of paraformaldehyde-fixed HeLa, using CDC34(7470) antibody at 1:100 dilution. |
FAQ & Publications
Frequently Asked Questions
What applications has the mouse anti-Cdc34 monoclonal antibody (14B5) been validated for?
This antibody is suitable for Western blotting (WB), immunocytochemistry/immunofluorescence (ICC/IF), immunohistochemistry on paraffin-embedded sections (IHC-P), and immunoprecipitation (IP). Recommended dilutions are 1-5 µg/mL for immunoblotting and immunoprecipitation.
How should the mouse anti-Cdc34 monoclonal antibody (14B5) be stored to maintain stability?
The antibody should be stored at -20°C and is stable for at least one year under these conditions. It is recommended to avoid multiple freeze-thaw cycles to preserve antibody integrity.
What is the immunogen used to generate the mouse anti-Cdc34 monoclonal antibody (14B5)?
The immunogen is an N-terminus 6x-His tagged fusion protein encoding full-length human Cdc34 expressed in Escherichia coli.
Publications
| pmid | title | authors | citation |
|---|---|---|---|
| We haven't added any publications to our database yet. | |||
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Protocols
| relevant to this product |
|---|
| Western blot IHC ICC |
Documents
| Batch Number | QC File | SDS |
|---|---|---|
| To view batch-specific Safety Datasheets and Quality Certificates associated with your account, please Log In. | ||
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.